Predictors of local recurrence and its impact on survival after glansectomy for penile cancer: time to challenge the dogma?


Journal

BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721

Informations de publication

Date de publication:
05 2021
Historique:
pubmed: 13 11 2020
medline: 21 9 2021
entrez: 12 11 2020
Statut: ppublish

Résumé

To identify predictive pathological factors for local recurrence (LR) and to study the impact of LR on survival in patients treated with glansectomy for penile squamous cell carcinoma (pSCC). We retrospectively studied patients treated with glansectomy at international, high-volume reference centres. We analysed histopathological predictors of LR, stratified patients into risk groups based on the number of risk factors present, and studied the impact of LR on survival outcomes using Kaplan-Meier survival analysis and stepwise Cox proportional hazards regression models. Subsequently, we performed sensitivity analyses excluding margin-positive cases, pT3 disease, and cN+ disease, or all of these factors. Across nine institutions, 897 patients were included, of whom 94 experienced LR. On multivariable analysis, presence of high-grade disease and pT3 stage were independent predictors of LR. LR-free survival rates significantly differed according to the number of risk factors present, with a hazard ratio (HR) of 1.90 (95% confidence interval [CI] 1.17-3.07; P = 0.01) for the intermediate-risk group (one risk factor) and 6.11 (95% CI 3.47-10.77; P < 0.001) for the high-risk group (two risk factors), using the low-risk group (no risk factors) as reference. Patients who experienced LR had significantly worse overall survival (OS; HR 2.89, 95% CI 2.02-4.14; P < 0.001) and cancer-specific survival (CSS; HR 5.64, 95% CI 3.45-9.22; P < 0.001). LR (HR 3.82, 95% CI 2.14-6.8; P < 0.001), lymphovascular invasion and cN status were significant predictors of decreased CSS. LR remained a strong predictor of both OS and CSS in all sensitivity analyses. Pathological T3 stage and presence of high-grade disease were independent histopathological predictors of LR after glansectomy for primary pSCC, which allowed risk stratification into three groups with significantly different risk of developing LR. Additionally, LR is related to poor OS and CSS, indicating that LR is a manifestation of underlying aggressive disease and clearly challenging the dogma of using organ-sparing surgery whenever possible since survival is unaffected by higher LR rates.

Identifiants

pubmed: 33180969
doi: 10.1111/bju.15297
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

606-613

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2020 The Authors BJU International © 2020 BJU International Published by John Wiley & Sons Ltd.

Références

Leijte JAP, Kirrander P, Antonini N, Windahl T, Horenblas S. Recurrence patterns of squamous cell carcinoma of the penis: recommendations for follow-up based on a two-centre analysis of 700 patients. Eur Urol 2008; 54: 161-9
Djajadiningrat RS, van Werkhoven E, Meinhardt W et al. Penile sparing surgery for penile cancer-does it affect survival? J Urol 2014; 192: 120-6
Philippou P, Shabbir M, Malone P et al. Conservative surgery for squamous cell carcinoma of the penis: resection margins and long-term oncological control. J Urol 2012; 188: 803-8
Sri D, Sujenthiran A, Lam W et al. A study into the association between local recurrence rates and surgical resection margins in organ-sparing surgery for penile squamous cell cancer. BJU Int 2018; 122: 576-82
Minhas S, Kayes O, Hegarty P, Kumar P, Freeman A, Ralph D. What surgical resection margins are required to achieve oncological control in men with primary penile cancer? BJU Int 2005; 96: 1040-3
Burnett AL. Penile preserving and reconstructive surgery in the management of penile cancer. Nat Rev Urol 2016; 13: 249-57
Scarberry K, Angermeier KW, Montague D, Campbell S, Wood HM. Outcomes for organ-preserving surgery for penile cancer. Sex Med 2015; 3: 62-6
Hakenberg OW, Compérat EM, Minhas S, Necchi A, Protzel C, Watkin N. EAU guidelines on penile cancer: 2014 update. Eur Urol 2015; 67: 142-50
Amin MB, Greene FL, Edge SB et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 2017; 67: 93-9
Baumgarten A, Chipollini J, Yan S et al. Penile sparing surgery for penile cancer: a multicenter international retrospective cohort. J Urol 2018; 199: 1233-7
Spiess PE. New treatment guidelines for penile cancer. J Natl Compr Cancer Netw 2013; 11: 659-62
Smith Y, Hadway P, Biedrzycki O, Perry MJA, Corbishley C, Watkin NA. Reconstructive surgery for invasive squamous carcinoma of the glans penis. Eur Urol 2007; 52: 1179-85
Albersen M, Parnham A, Joniau S et al. Predictive factors for local recurrence after glansectomy and neoglans reconstruction for penile squamous cell carcinoma. Urol Oncol Semin Orig Investig 2018; 36: 141-6
Tang DH, Yan S, Ottenhof SR et al. Glansectomy as primary management of penile squamous cell carcinoma: an international study collaboration. Urology 2017; 109: 140-4
Veeratterapillay R, Teo L, Asterling S, Greene D. Oncologic outcomes of penile cancer treatment at a UK supraregional center. Urology 2015; 85: 1097-103

Auteurs

Eduard Roussel (E)

Department of Urology, University Hospitals Leuven, Leuven, Belgium.

Eline Peeters (E)

Department of Urology, University Hospitals Leuven, Leuven, Belgium.

Joren Vanthoor (J)

Department of Urology, University Hospitals Leuven, Leuven, Belgium.

Giorgio Bozzini (G)

Department of Urology, ASST Valle Olona, Busto A. Varese, Lombardia, Italy.

Asif Muneer (A)

Department of Urology and NIHR Biomedical Research Centre, University College London Hospital, London, UK.

Ben Ayres (B)

Department of Urology, NHS Foundation Trust, St.-George's University Hospitals, London, UK.

Denosshan Sri (D)

Department of Urology, NHS Foundation Trust, St.-George's University Hospitals, London, UK.

Nick Watkin (N)

Department of Urology, NHS Foundation Trust, St.-George's University Hospitals, London, UK.

Rohit Bhattar (R)

Department of Urology, The Christie NHS Foundation Trust, Manchester, UK.

Arie Parnham (A)

Department of Urology, The Christie NHS Foundation Trust, Manchester, UK.

Vijay Sangar (V)

Department of Urology, The Christie NHS Foundation Trust, Manchester, UK.

Maurice Lau (M)

Department of Urology, The Christie NHS Foundation Trust, Manchester, UK.

Gregory Joice (G)

Department of Urology, Johns Hopkins Medical Institutes, Baltimore, MD, USA.

Trinity J Bivalacqua (TJ)

Department of Urology, Johns Hopkins Medical Institutes, Baltimore, MD, USA.

Juan Chipollini (J)

Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA.

Philippe E Spiess (PE)

Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA.

Georgios Hatzichristodoulou (G)

Department of Urology, Martha-Maria Hospital Nuremberg, Nuremberg, Germany.

Lieke de Vries (L)

Department of Urology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

Oscar Brouwer (O)

Department of Urology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

Maarten Albersen (M)

Department of Urology, University Hospitals Leuven, Leuven, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH